RAAS inhibitors, including angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), decrease the adverse effects of angiotensin II and aldosterone, which are major contributors to cardiac remodeling, fibrosis, and cellular dysfunction in heart failure. This evidence concerns the gene ACE and heart failure.